Low Disclosure of PrEP Nonadherence and HIV-Risk Behaviors Associated With Poor HIV PrEP Adherence in the HPTN 067/ADAPT Study

J Acquir Immune Defic Syndr. 2019 Sep 1;82(1):34-40. doi: 10.1097/QAI.0000000000002103.

Abstract

Objective: We evaluated the relationship between 2 types of social relationships, ie, (1) external support for use of HIV pre-exposure prophylaxis (PrEP) and related study supplies and (2) participants' disclosure of PrEP use and condom use and HIV PrEP adherence among daily-dosing regimen participants in HIV Prevention Trials Network (HPTN) 067, an open-label trial of oral tenofovir (TFV) disoproxil fumarate (TDF) 300 mg/emtricitabine (FTC) 200 mg.

Methods: Using HPTN 067 survey data, we developed scales examining (1) Low Perceived External Support for PrEP: low perceived support by others for PrEP use or perceived negative reactions to the pill case (scoring ranges from 0 to 2) and (2) Participant-Staff Disclosure Challenges Scale, which identifies challenges to sharing nonuse of PrEP or condoms to study staff (scoring ranges from 0 to 4); these scales are the primary independent variables. Adherence, the dependent variable, was determined using log-transformed plasma TFV concentrations. generalized estimating equation (GEE) linear regression was used to assess the association between both scales and adherence.

Results: Participants (n = 161) included HIV-uninfected women in South Africa, and men who have sex with men and transgender women, in Thailand and the United States. In multivariable analyses, higher scores in the Participant-Staff Disclosure Challenges Scale were significantly associated with lower PrEP adherence [exp(β) = 0.62, 95% CI: (0.46 to 0.84); P = 0.002] as were increased days since the last PrEP dose [exp(β) = 0.73, 95% CI: (0.65 to 0.83); P ≤ 0.001].

Conclusions: Given the association with adherence, study staff-participant interactions and participants' disclosure of PrEP challenges may be worthwhile intervention targets for improving PrEP adherence in confirmatory studies.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Acquired Immunodeficiency Syndrome / drug therapy
  • Acquired Immunodeficiency Syndrome / prevention & control
  • Adult
  • Anti-HIV Agents / administration & dosage
  • Anti-HIV Agents / therapeutic use
  • Condoms
  • Directly Observed Therapy
  • Disclosure*
  • Drug Therapy, Combination
  • Emtricitabine / administration & dosage
  • Emtricitabine / therapeutic use
  • Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination / administration & dosage
  • Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination / therapeutic use
  • Female
  • HIV Infections / drug therapy*
  • HIV Infections / prevention & control*
  • Homosexuality, Male
  • Humans
  • Male
  • Medication Adherence / statistics & numerical data
  • Middle Aged
  • Pre-Exposure Prophylaxis / statistics & numerical data*
  • Risk-Taking
  • Sexual and Gender Minorities
  • Social Networking*
  • South Africa / epidemiology
  • Surveys and Questionnaires
  • Tenofovir / administration & dosage
  • Tenofovir / therapeutic use
  • Thailand / epidemiology
  • United States / epidemiology
  • Young Adult

Substances

  • Anti-HIV Agents
  • Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
  • Tenofovir
  • Emtricitabine